Inclusion Criteria:  Patient requires a percutaneous valve-in-valve procedure due to a failed bioprosthetic valve and is at risk for TAVR-induced coronary artery obstruction, based on the local Heart Team decision. Written informed consent to participate in the study obtained from the subject or subject's legal representative, according to local regulations, prior to initiation of any study mandated procedure.  Exclusion Criteria:  An excessive aortic valve leaflet Calcium morphology or anatomy not suitable for the use of the ShortCut™ device. Coronary, carotid or vertebral disease that, in the opinion of the local Heart Team, should be treated; or treatment of such disease ≤ 1 month prior to index procedure. CVA or TIA ≤ 6 months prior to index procedure, or severe neurological disability. Myocardial infarction (MI) ≤ 6 weeks prior to index procedure. Hemodynamic or respiratory instability. Left ventricle ejection fraction < 30%. Ongoing severe infection, sepsis or endocarditis. Renal insufficiency, unless on dialysis. Need for emergency surgery for any reason. Life expectancy is less than 90 days.